



## AirDuo™ RespiClick® (fluticasone/salmeterol) – New drug and first-time generic launch

- On April 20, 2017, [Teva announced](#) the simultaneous launch of [AirDuo RespiClick \(fluticasone/salmeterol\)](#) and its authorized generic for the treatment of asthma in patients aged 12 years and older.
  - AirDuo RespiClick is not indicated for the relief of acute bronchospasm.
- AirDuo RespiClick and its authorized generic are available as breath-activated, multi-dose dry powder inhalers of fluticasone/salmeterol in three strengths: 55 mcg/14 mcg, 113 mcg/14 mcg, and 232 mcg/14 mcg.
- Similar to other asthma products containing long-acting beta<sub>2</sub>-adrenergic agonists, AirDuo RespiClick carries a boxed warning for asthma-related death.
- Other currently available brand fluticasone/salmeterol combination products include [Advair Diskus®](#) and [Advair® HFA](#). Refer to individual drug labels for indication information.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.